Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Starting in April $TLRY cannabis flower will be available in Portuguese pharmacies.
15 grams for 150 € at retail.
This is the first cannabis product approved by the Portuguese health agency, but other are in the pipeline
https://t.co/h2neXEiS0g
Starting in April $TLRY cannabis flower will be available in Portuguese pharmacies.
— Alfredo Pascual, CFA 🥨🧉 (@alfrep28) February 25, 2021
15 grams for 150 € at retail.
This is the first cannabis product approved by the Portuguese health agency, but other are in the pipeline.https://t.co/h2neXEiS0g
Manitoba harvest
VP breaks the tie?
I hope we’re not going up just because of the GameStop move today. TLRY AND APHA CEOS ON CLOSING BELL SOON TO DISCUSS MERGER. 4-5pm est CNBC
Uhm dems a majority in all 3 branches..
Simon and Kennedy are both scheduled to appear on CNBC's "Closing Bell" today
Aphria Inc. Continues To Build Out A Robust Cannabis Platform To Dominate The European Union
STOCKS Feb 24, 2021 • 7:40 AM EST
3 MIN READ • BY MICHAEL BERGER
Earlier this week, Aphria Inc. (APHA.TO) (APHA) reported a major development as it relates to the European Union’s (EU) cannabis market and believes that our readers need to be aware of the significance of the announcement as it relates to the previously announced mega-merger with Tilray Inc. (TLRY).
As standalone businesses, both Aphria and Tilray are well positioned to capitalize on the European cannabis market. Following the completion of the mega-merger, the combined company will have the most market share in the EU and in Canada’s legal medical and recreational cannabis industries.
CC Pharma is a wholly owned subsidiary of Aphria and serves as the EU distribution arm of the business. During the last year, CC Pharma has reported impressive growth and it has played a key role in Aphria’s success in the EU.
The major development that Aphria reported earlier this week is related to a commercial supply agreement that CC Pharma entered into with Materia Deutschland. Under the agreement, CC Pharma will distribute Aphria-branded flower products across Materia Deutschland’s pharmacy network in Germany. Materia is a medical cannabis and wellness company that is focused on expanding its portfolio of medical cannabis products being offered to pharmacies in the EU (especially Germany).
Under the terms of the agreement, CC Pharma will import, and batch release the products, with Materia Deutschland taking responsibility for pharmacy sales and fulfillment. By adding Aphria’s flower to Materia Deutschland’s portfolio of cannabis products, it is enhancing the types of cannabis products that are being offered to customers and increase the amount of market share that it has in Germany. In the coming weeks, Materia will start to distribute and sell Aphria-branded products to pharmacies and we are bullish on the growth prospects that are associated with the relationship.
Tilray operates a state-of-the-art EU GMP facility in Portugal and we expect the facility to serve as a major growth driver for the combined company. Once the acquisition is completed, we expect the combined company to record a massive spike in revenue that is derived from the EU’s cannabis market. Going forward, we expect the combined company to discover substantial synergies as it relates to the EU and consider this to be a crucial pillar of the long-term story.
We are excited about the transaction for a variety of reasons and want to highlight what we consider to be the most significant:
We expect the combined company to find massive synergies between the businesses
the combined company is expected to have a leading position in Canada’s recreational cannabis market
Aphria’s acquisition of Sweetwater Brewing Company provides the combined company with substantial infrastructure to capitalize on the US market
the combined company will have a leading position in strategic international markets
the transaction will further enhance the diversity and the strength of the leadership team
We are bullish on the growth prospects that are associated with the Tilray-Aphria merger agreement and believe that our readers need to be aware of the opportunity. If you are interested in learning more about the Aphria-Tilray merger, please send an email to support@technical420.com with the subject “Aphria-Tilray Merger” to be added to our distribution list.
https://www.technical420.com/cannabis-article/aphria-inc-continues-to-build-out-a-robust-cannabis-platform-to-dominate-the-european-union/
Aphria Inc. Continues To Build Out A Robust Cannabis Platform To Dominate The European Union
STOCKS Feb 24, 2021 • 7:40 AM EST
3 MIN READ • BY MICHAEL BERGER
Earlier this week, Aphria Inc. (APHA.TO) (APHA) reported a major development as it relates to the European Union’s (EU) cannabis market and believes that our readers need to be aware of the significance of the announcement as it relates to the previously announced mega-merger with Tilray Inc. (TLRY).
As standalone businesses, both Aphria and Tilray are well positioned to capitalize on the European cannabis market. Following the completion of the mega-merger, the combined company will have the most market share in the EU and in Canada’s legal medical and recreational cannabis industries.
CC Pharma is a wholly owned subsidiary of Aphria and serves as the EU distribution arm of the business. During the last year, CC Pharma has reported impressive growth and it has played a key role in Aphria’s success in the EU.
The major development that Aphria reported earlier this week is related to a commercial supply agreement that CC Pharma entered into with Materia Deutschland. Under the agreement, CC Pharma will distribute Aphria-branded flower products across Materia Deutschland’s pharmacy network in Germany. Materia is a medical cannabis and wellness company that is focused on expanding its portfolio of medical cannabis products being offered to pharmacies in the EU (especially Germany).
Under the terms of the agreement, CC Pharma will import, and batch release the products, with Materia Deutschland taking responsibility for pharmacy sales and fulfillment. By adding Aphria’s flower to Materia Deutschland’s portfolio of cannabis products, it is enhancing the types of cannabis products that are being offered to customers and increase the amount of market share that it has in Germany. In the coming weeks, Materia will start to distribute and sell Aphria-branded products to pharmacies and we are bullish on the growth prospects that are associated with the relationship.
Tilray operates a state-of-the-art EU GMP facility in Portugal and we expect the facility to serve as a major growth driver for the combined company. Once the acquisition is completed, we expect the combined company to record a massive spike in revenue that is derived from the EU’s cannabis market. Going forward, we expect the combined company to discover substantial synergies as it relates to the EU and consider this to be a crucial pillar of the long-term story.
We are excited about the transaction for a variety of reasons and want to highlight what we consider to be the most significant:
We expect the combined company to find massive synergies between the businesses
the combined company is expected to have a leading position in Canada’s recreational cannabis market
Aphria’s acquisition of Sweetwater Brewing Company provides the combined company with substantial infrastructure to capitalize on the US market
the combined company will have a leading position in strategic international markets
the transaction will further enhance the diversity and the strength of the leadership team
We are bullish on the growth prospects that are associated with the Tilray-Aphria merger agreement and believe that our readers need to be aware of the opportunity. If you are interested in learning more about the Aphria-Tilray merger, please send an email to support@technical420.com with the subject “Aphria-Tilray Merger” to be added to our distribution list.
https://www.technical420.com/cannabis-article/aphria-inc-continues-to-build-out-a-robust-cannabis-platform-to-dominate-the-european-union/
aphria incTilray
Creating the largest global cannabis company by revenue
Aphria and Tilray’s complementary, scalable medical and adult-use cannabis businesses are expected to strengthen the combined company’s leadership position in Canada.
The business combination is expected to expand Aphria’s and Tilray’s U.S. and international reach through state-of-the-art cultivation and manufacturing facilities, a diversified product portfolio and its distribution footprint and robust supply chain.
The business combination is expected to provide operational efficiencies that are anticipated to generate approximately C$100 million (US$78 million) of annual pre-tax annual cost synergies within 24 months of the completion of the business combination.
APHRIA INC.
aphria inc.
Bingo
Ptite Pof
Good Supply
Solei
RIFF
Broken Coast
Sweet Water
420 Strain Bones
420 EPA
TILRAY, INC.
Tilray
High Park
Manitoba Harvest
Everie
Chowie Wowie
Marley Natural
The Batch
Canaca
DuBon
Grail
Pollen
Sign up to receive updates about the transaction
Submit
This form collects your name and email so that we can add you to our distribution list for updates from Aphria Inc. and Tilray, Inc. Check out our privacy policies for the full story on how we protect and manage your submitted data.
By clicking sign up, I consent to having Aphria Inc. and Tilray, Inc. collect my name and email.
APHRIA + TILRAY
A Message from the CEOs
Irwin D. Simon
“This is an exciting day for both companies including our 2,500 employees, for the cannabis industry, and for patients and consumers around the world. We are bringing together two world-class companies that share a culture of innovation, brand development and cultivation to enhance our Canadian, U.S., and international scale as we pursue opportunities for accelerated growth with the strength and flexibility of our balance sheet and access to capital. Our highly complementary businesses create a combined company with a leading branded product portfolio, including the most comprehensive Cannabis 2.0 product offerings for patients and consumers, along with significant synergies across our operations in Canada, Europe and the United States. Our combination with Tilray aligns with our strategic focus and emphasis on our highest return priorities as we strive to generate value for all stakeholders. I am honoured to work with Brendan Kennedy, a pioneer in the cannabis industry, and the Tilray team as they join forces with our talented employees at Aphria. I look forward to leading the talented teams of both Aphria and Tilray as we seek to create a leading global cannabis and consumer packaged goods company with a portfolio of medical, wellness and adult-use brands consumers love.”
- Irwin D. Simon, Chairman & CEO, Aphria Inc.
Brendan Kennedy
“We are thrilled to bring together two cannabis industry leaders. At this nascent stage of development and expansion of the global cannabis market, we believe companies with leading geographic scale, product range and brand expertise are most likely to benefit long-term. By leveraging our combined strengths and capabilities, we expect to be able to meet the needs of consumers more effectively all over the world and advance patient care. With a strong financial profile, low-cost production, leading brands, distribution network and unique partnerships, we believe the Combined Company will be well-positioned to deliver sustainable, attractive returns for stockholders. I look forward to working with Irwin and the Combined Company’s management team to make our consumer products more accessible around the world.”
- Brendan Kennedy: CEO, Tilray, Inc.
https://www.aphriatilraytogether.com/
aphria incTilray
Creating the largest global cannabis company by revenue
Aphria and Tilray’s complementary, scalable medical and adult-use cannabis businesses are expected to strengthen the combined company’s leadership position in Canada.
The business combination is expected to expand Aphria’s and Tilray’s U.S. and international reach through state-of-the-art cultivation and manufacturing facilities, a diversified product portfolio and its distribution footprint and robust supply chain.
The business combination is expected to provide operational efficiencies that are anticipated to generate approximately C$100 million (US$78 million) of annual pre-tax annual cost synergies within 24 months of the completion of the business combination.
APHRIA INC.
aphria inc.
Bingo
Ptite Pof
Good Supply
Solei
RIFF
Broken Coast
Sweet Water
420 Strain Bones
420 EPA
TILRAY, INC.
Tilray
High Park
Manitoba Harvest
Everie
Chowie Wowie
Marley Natural
The Batch
Canaca
DuBon
Grail
Pollen
Sign up to receive updates about the transaction
Submit
This form collects your name and email so that we can add you to our distribution list for updates from Aphria Inc. and Tilray, Inc. Check out our privacy policies for the full story on how we protect and manage your submitted data.
By clicking sign up, I consent to having Aphria Inc. and Tilray, Inc. collect my name and email.
APHRIA + TILRAY
A Message from the CEOs
Irwin D. Simon
“This is an exciting day for both companies including our 2,500 employees, for the cannabis industry, and for patients and consumers around the world. We are bringing together two world-class companies that share a culture of innovation, brand development and cultivation to enhance our Canadian, U.S., and international scale as we pursue opportunities for accelerated growth with the strength and flexibility of our balance sheet and access to capital. Our highly complementary businesses create a combined company with a leading branded product portfolio, including the most comprehensive Cannabis 2.0 product offerings for patients and consumers, along with significant synergies across our operations in Canada, Europe and the United States. Our combination with Tilray aligns with our strategic focus and emphasis on our highest return priorities as we strive to generate value for all stakeholders. I am honoured to work with Brendan Kennedy, a pioneer in the cannabis industry, and the Tilray team as they join forces with our talented employees at Aphria. I look forward to leading the talented teams of both Aphria and Tilray as we seek to create a leading global cannabis and consumer packaged goods company with a portfolio of medical, wellness and adult-use brands consumers love.”
- Irwin D. Simon, Chairman & CEO, Aphria Inc.
Brendan Kennedy
“We are thrilled to bring together two cannabis industry leaders. At this nascent stage of development and expansion of the global cannabis market, we believe companies with leading geographic scale, product range and brand expertise are most likely to benefit long-term. By leveraging our combined strengths and capabilities, we expect to be able to meet the needs of consumers more effectively all over the world and advance patient care. With a strong financial profile, low-cost production, leading brands, distribution network and unique partnerships, we believe the Combined Company will be well-positioned to deliver sustainable, attractive returns for stockholders. I look forward to working with Irwin and the Combined Company’s management team to make our consumer products more accessible around the world.”
- Brendan Kennedy: CEO, Tilray, Inc.
https://www.aphriatilraytogether.com/
Re: funman This deal is for Germany (I think) Which is a huge market for medical...
This EU deal proves to other countries we can do it. The largest cannabis company in the world.
Yeah this proves to other countries we can do it. The largest cannabis company in the world.
THIS IS GREAT NEWS! Aphria’s Subsidiary CC Pharma Announces Major European Supply Agreement
STOCKS Feb 23, 2021 • 7:06 AM EST
3 MIN READ • BY MICHAEL BERGER
Materia, a medical cannabis and wellness company focused on the European market, is pleased to announce that its wholly-owned subsidiary Materia Deutschland GmbH, is expanding its portfolio of medical cannabis products being offered to pharmacies acrossGermany.
Materia Logo (CNW Group/Materia Ventures)
Materia Deutschland has entered into a commercial supply agreement with CC Pharma GmbH (” CC Pharma “), a wholly owned subsidiary of Aphria Inc., to distribute its high quality, Aphria-branded flower products across Materia Deutschland’s pharmacy network throughout Germany . Under the terms of this agreement, CC Pharma will import and batch release the products, with Materia Deutschland taking responsibility for pharmacy sales and fulfillment.
Separately, Materia Deutschland has also entered into an agreement with an EU-GMP certified supplier of dronabinol, a pure THC API that accounts for approximately 35% of all publicly reimbursed medical cannabis prescriptions in Germany 1 , including finished pharmaceuticals.
“We have been intentionally selective in growing our portfolio, to ensure that new products will satisfy patients’ evolving needs and bear the highest standards of quality,” said Sebastian Blöte, Managing Director, Germany , of Materia Deutschland. “We are proud to work with partners who share our unwavering commitment to patient care and an enhanced societal understanding of cannabis’ medical potential.”
The addition of Aphria flower and dronabinol will bolster Materia Deutschland’s offering to customers and accelerate its growth potential in the German market. Materia has already commenced sales of dronabinol, while sales of Aphria-branded products to pharmacies will begin in the coming weeks.
________________
1 GKV-Spitzenverband
About Materia
Materia’s vision is to be the enabler of global cannabis access. Materia is developing a robust pharmaceutical manufacturing and distribution ecosystem to grow the legal cannabinoid market across Europe . With its research-driven team and regulatory expertise, Materia focuses on the high-margin downstream activities of processing, formulation and distribution into markets wherever there is a patient in need of cannabis medicine or CBD consumers seeking innovative new products.
CAUTIONARY STATEMENT:
All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and legal uncertainties; access to financing; the delay or failure to receive regulatory approvals; and other factors. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Materia does assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
SOURCE Materia Ventures
https://www.technical420.com/cannabis-article/aphrias-subsidiary-cc-pharma-announces-major-european-supply-agreement/
THIS IS GREAT NEWS! Aphria’s Subsidiary CC Pharma Announces Major European Supply Agreement
STOCKS Feb 23, 2021 • 7:06 AM EST
3 MIN READ • BY MICHAEL BERGER
Materia, a medical cannabis and wellness company focused on the European market, is pleased to announce that its wholly-owned subsidiary Materia Deutschland GmbH, is expanding its portfolio of medical cannabis products being offered to pharmacies acrossGermany.
Materia Logo (CNW Group/Materia Ventures)
Materia Deutschland has entered into a commercial supply agreement with CC Pharma GmbH (” CC Pharma “), a wholly owned subsidiary of Aphria Inc., to distribute its high quality, Aphria-branded flower products across Materia Deutschland’s pharmacy network throughout Germany . Under the terms of this agreement, CC Pharma will import and batch release the products, with Materia Deutschland taking responsibility for pharmacy sales and fulfillment.
Separately, Materia Deutschland has also entered into an agreement with an EU-GMP certified supplier of dronabinol, a pure THC API that accounts for approximately 35% of all publicly reimbursed medical cannabis prescriptions in Germany 1 , including finished pharmaceuticals.
“We have been intentionally selective in growing our portfolio, to ensure that new products will satisfy patients’ evolving needs and bear the highest standards of quality,” said Sebastian Blöte, Managing Director, Germany , of Materia Deutschland. “We are proud to work with partners who share our unwavering commitment to patient care and an enhanced societal understanding of cannabis’ medical potential.”
The addition of Aphria flower and dronabinol will bolster Materia Deutschland’s offering to customers and accelerate its growth potential in the German market. Materia has already commenced sales of dronabinol, while sales of Aphria-branded products to pharmacies will begin in the coming weeks.
________________
1 GKV-Spitzenverband
About Materia
Materia’s vision is to be the enabler of global cannabis access. Materia is developing a robust pharmaceutical manufacturing and distribution ecosystem to grow the legal cannabinoid market across Europe . With its research-driven team and regulatory expertise, Materia focuses on the high-margin downstream activities of processing, formulation and distribution into markets wherever there is a patient in need of cannabis medicine or CBD consumers seeking innovative new products.
CAUTIONARY STATEMENT:
All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and legal uncertainties; access to financing; the delay or failure to receive regulatory approvals; and other factors. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Materia does assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
SOURCE Materia Ventures
https://www.technical420.com/cannabis-article/aphrias-subsidiary-cc-pharma-announces-major-european-supply-agreement/
Re: Las3r (APHA) “S&P 500 futures fall amid Big Tech's slide, Nasdaq futures drop 1.5%”
Good point. Will it be a big slide?
Looks like bitcoin tanked, so bringing down speculative stocks with them....?
Looks like bitcoin tanked, so bringing down speculative stocks with them....?
And yet we’re up again..
Yep! “ The pending merger between it and Aphria is expected to close in the second quarter of 2021. The combined entity will still use the Tilray name. But the company will look much different after the merger with Aphria. Aphria shareholders will own the majority of the combined company (62%). Current Aphria chairman and CEO Irwin Simon will hold those same positions in the post-merger organization. Aphria will have seven seats on the board of directors compared to only two current Tilray directors plus a new director to be named. In reality, the "new" Tilray will be more Aphria than Tilray. Tilray deserves the hoorays for its Q4 update. But, in a real sense, the company could only have one final hurrah on the way.”
Re: funman ?? “The pending merger between it and Aphria is expected to close in the second quarter of 2021. The combined entity will still use the Tilray name. But the company will look much different after the merger with Aphria. Aphria shareholders will own the majority of the combined company (62%). Current Aphria chairman and CEO Irwin Simon will hold those same positions in the post-merger organization. Aphria will have seven seats on the board of directors compared to only two current Tilray directors plus a new director to be named. In reality, the "new" Tilray will be more Aphria than Tilray. Tilray deserves the hoorays for its Q4 update. But, in a real sense, the company could only have one final hurrah on the way.”
IMO It’s like getting in on Netflix when it was $1.67
IMO It’s like getting in on Netflix when it was $1.67
TLRY earnings call...it is VERY positive. IMO. They talk a lot about Aphria, all is good!
TLRY earnings call...it is VERY positive. IMO. They talk a lot about Aphria, all is good????????????
Im long. In my opinion, I don’t think it would be a bloodbath if earnings are a miss for TLRY. This is now about Irwin coming in from and taking over the ship. It’s about his contacts... his direction now. He knows what he’s getting into.
In my opinion, I don’t think it would be a bloodbath if earnings are a miss. This is now about Irwin coming in from Aphria and taking over the ship. It’s about his contacts... his direction now. He knows what he’s getting into.
8:57am 2/16/2021 UPDATE: To profit from planned merger of Tilray and Aphria, buy Aphria, says this analyst
Mentioned: APHA TLRY
Ciara Linnane
Investors seeking to profit from the merger of Canadian cannabis companies Tilray Inc. and Aphria Inc. are best to do so by buying shares of Aphria, which are trading at a 51% discount over the merger conversion price, Cantor Fitzgerald analyst Pablo Zuanic said Tuesday.
Zuanic reiterated his overweight rating on Aphria stock (APHA.T) and raised his 12-month price target to C$32.50 ($25.71) from C$26.00. He also stuck with his neutral rating on Tilray (TLRY), while raising his price target to $30.25 from $24.20.
"The recent significant bout of volatility in Canadian cannabis stocks may be another deterrent for investors looking at this subsector (aside of mixed fundamentals and valuation)," Zuanic wrote in a note to clients. "But with US MSOs (multi-state operators) landlocked, we continue to think the larger better managed Canadian LPs deserve a premium for global growth potential."
Read now:Aurora Cannabis stock slides as analysts weigh in on weak quarterly earnings and one downgrades to sell (https://www.marketwatch.com/story/aurora-cannabis-stock-slides-as-analysts-weigh-in-on-weak-quarterly-earnings-and-one-downgrades-to-sell-11613156282?mod=cannabis-watch)
The planned merger continues to make strategic sense and the combined company could eventually look attractive to consumer packaged goods companies, and could attract a U.S. suitor before the end of cannabis prohibition, he wrote.
Read: Cannabis stocks nosedive as rally driven by hopes for U.S. legal reforms comes to a screeching halt (https://www.marketwatch.com/story/cannabis-stocks-nosedive-as-rally-driven-by-hopes-for-u-s-reforms-comes-to-a-screeching-halt-11613069414)
The combined company will have close to two times the size of Canopy Growth Corp.'s (WEED.T) share of the Canadian recreational cannabis market, and offers 51% upside for Aphria shares and about 4% for Tilray, he wrote.
Under the terms of the deal, (https://www.marketwatch.com/story/tilray-stock-rockets-after-reverse-merger-deal-with-aphria-to-create-largest-global-cannabis-company-11608128018)Aphria shareholders will received 0.8381 Tilray shares for each share owned.
"Thus, using TLRY's closing price of US$29 on 2/12, this would mean APHAshares would be worth C$31," said Zuanic. Cantor is not expecting the deal terms to be renegotiated, but rather views the gap as a result of recent volatility in Canadian cannabis stocks with Tilray the most liquid given its Nasdaq listing.
Read now: Cannabis stocks rally after Chuck Schumer leads drive for reforms that may end federal prohibition (https://www.marketwatch.com/story/cannabis-stocks-rally-after-chuck-schumer-leads-drive-for-reforms-that-will-end-federal-prohibition-11612292635?mod=cannabis-watch)
"We would put the likelihood of other bidders emerging at less than5% (not for tiny TLRY on its own) and renegotiated terms at less than 20% (we do not think TLRY has much bargaining power)," said the note.
Aphria shares were up 8.4% premarket and have gained 293% in the last 12 months. Tilray's stock was up 6.4% and has gained 67% in the last 12 months.
The Cannabis ETF (THCX), up 3.4% premarket, has gained 94% in the same time frame, while the S&P 500 has gained 16%.
For more of MarketWatch's cannabis coverage, see: Cannabis Watch (https://www.marketwatch.com/column/cannabis-watch?mod=breadcrumb)
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
February 16, 2021 08:57 ET (13:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Revenues Continue to Jump for Legal Cannabis Market Expected to Exceed $73 Billion By 2027
Financialnewsmedia.com News Commentary
https://www.prnewswire.com/news-releases/revenues-continue-to-jump-for-legal-cannabis-market-expected-to-exceed-73-billion-by-2027-301228625.html
Revenues Continue to Jump for Legal Cannabis Market Expected to Exceed $73 Billion By 2027
Financialnewsmedia.com News Commentary
https://www.prnewswire.com/news-releases/revenues-continue-to-jump-for-legal-cannabis-market-expected-to-exceed-73-billion-by-2027-301228625.html
Investors seeking to profit from the merger of Canadian cannabis companies Tilray Inc. and Aphria Inc. are best to do so by buying shares of Aphria, which are trading at a 51% discount over the merger conversion price, Cantor Fitzgerald analyst Pablo Zuanic said Tuesday.
https://www.marketwatch.com/story/to-profit-from-planned-merger-of-tilray-and-aphria-buy-aphria-says-this-analyst-11613482075?siteid=yhoof2
4/20 lol
APHRIA ON German market up 3.88% today.
Re: John Legend (TLRY board) ??! “Given the solid turnaround in the Canadian legal weed market, Tilray stock is still up for grabs at 19 times forward sales. And the real crown jewel -- its potential to enter the U.S. THC market in the face of looming federal decriminalization -- is still to come.” Merger in April? 4/20?
Tilray $TLRY just announced they be reporting their Q4 earnings after the markets close on Wednesday, February 17th STOCK MARKET NEWS
Tilray $TLRY just announced they be reporting their Q4 earnings after the markets close on Wednesday, February 17th STOCK MARKET NEWS